Literature DB >> 17934105

Regulatory T cells and toll-like receptors: regulating the regulators.

Roger Sutmuller1, Anja Garritsen, Gosse J Adema.   

Abstract

Regulatory T cells (Treg) play a crucial role in maintaining control of leucocytes. Several studies have shown that in vivo Treg depletion results in autoimmune syndromes like thyroiditis, gastritis, diabetes mellitus and colitis, but at the same time, may also result in improved anti-tumour vaccination. Although Treg are recognised to maintain peripheral tolerance in healthy individuals, recent research has shown that Treg also suppress immune responses during infections to prevent tissue damage. How the Treg themselves are regulated is still under investigation. Their suppressive activity must be regulated in order to allow for the effective elimination of pathogens. Until recently, this control of Treg function was found to be through modulation via cytokines or by stimulation via co-stimulatory molecules on antigen-presenting cells. It is now demonstrated, however, that the presence of pathogens can be communicated to Treg directly through toll-like receptors (TLRs). Up until now, Treg have been reported to respond to ligands for TLR2, 4, 5 and 8, and different TLRs can have alternative effects on Treg resulting in more suppression or, in contrast, abrogation of suppression. As TLRs can also recognise endogenous proteins, such as heat shock proteins, it is tempting to speculate on the role of these proteins in modulating Treg function during chronic inflammation. In this review, we will discuss the implications of TLR engagement on Treg and any consequences this may have for chronic autoinflammatory diseases like rheumatoid arthritis (RA).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17934105      PMCID: PMC2095279          DOI: 10.1136/ard.2007.078535

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  72 in total

Review 1.  Manifold mechanisms of Toll-like receptor-ligand recognition.

Authors:  Ken J Ishii; Cevayir Coban; Shizuo Akira
Journal:  J Clin Immunol       Date:  2005-11       Impact factor: 8.317

Review 2.  Expanding the effector CD4 T-cell repertoire: the Th17 lineage.

Authors:  Laurie E Harrington; Paul R Mangan; Casey T Weaver
Journal:  Curr Opin Immunol       Date:  2006-04-17       Impact factor: 7.486

3.  Human CD4+ T cells express TLR5 and its ligand flagellin enhances the suppressive capacity and expression of FOXP3 in CD4+CD25+ T regulatory cells.

Authors:  Natasha K Crellin; Rosa V Garcia; Omeed Hadisfar; Sarah E Allan; Theodore S Steiner; Megan K Levings
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

4.  Toll-like receptor 2 controls expansion and function of regulatory T cells.

Authors:  Roger P M Sutmuller; Martijn H M G M den Brok; Matthijs Kramer; Erik J Bennink; Liza W J Toonen; Bart-Jan Kullberg; Leo A Joosten; Shizuo Akira; Mihai G Netea; Gosse J Adema
Journal:  J Clin Invest       Date:  2006-01-19       Impact factor: 14.808

5.  Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function.

Authors:  Guangyong Peng; Zhong Guo; Yukiko Kiniwa; Kui Shin Voo; Weiyi Peng; Tihui Fu; Daniel Y Wang; Yanchun Li; Helen Y Wang; Rong-Fu Wang
Journal:  Science       Date:  2005-08-26       Impact factor: 47.728

6.  Interleukin-7 is a survival factor for CD4+ CD25+ T-cells and is expressed by diabetes-suppressive dendritic cells.

Authors:  Jo Harnaha; Jennifer Machen; Marietta Wright; Robert Lakomy; Alexis Styche; Massimo Trucco; Sami Makaroun; Nick Giannoukakis
Journal:  Diabetes       Date:  2006-01       Impact factor: 9.461

7.  Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta.

Authors:  Marina Ostroukhova; Zengbiao Qi; Timothy B Oriss; Barbara Dixon-McCarthy; Prabir Ray; Anuradha Ray
Journal:  J Clin Invest       Date:  2006-03-16       Impact factor: 14.808

Review 8.  FOXP3: of mice and men.

Authors:  Steven F Ziegler
Journal:  Annu Rev Immunol       Date:  2006       Impact factor: 28.527

9.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner.

Authors:  François Ghiringhelli; Cédric Ménard; Magali Terme; Caroline Flament; Julien Taieb; Nathalie Chaput; Pierre E Puig; Sophie Novault; Bernard Escudier; Eric Vivier; Axel Lecesne; Caroline Robert; Jean-Yves Blay; Jacky Bernard; Sophie Caillat-Zucman; Antonio Freitas; Thomas Tursz; Orianne Wagner-Ballon; Claude Capron; William Vainchencker; François Martin; Laurence Zitvogel
Journal:  J Exp Med       Date:  2005-10-17       Impact factor: 14.307

10.  Infected site-restricted Foxp3+ natural regulatory T cells are specific for microbial antigens.

Authors:  Isabelle J Suffia; Stacie K Reckling; Ciriaco A Piccirillo; Romina S Goldszmid; Yasmine Belkaid
Journal:  J Exp Med       Date:  2006-03-13       Impact factor: 14.307

View more
  26 in total

1.  Engagement of TLR2 reverses the suppressor function of conjunctiva CD4+CD25+ regulatory T cells and promotes herpes simplex virus epitope-specific CD4+CD25- effector T cell responses.

Authors:  Gargi Dasgupta; Aziz Alami Chentoufi; Sylvaine You; Payam Falatoonzadeh; Lourie Ann A Urbano; Ayesha Akhtarmalik; Kimberly Nguyen; Lilit Ablabutyan; Anthony B Nesburn; Lbachir BenMohamed
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-17       Impact factor: 4.799

2.  Effect of tiotropium bromide on expression of CD(8) (+)CD (25) (+)FoxP (3) (+) regulatory T cells in patients with stable chronic obstructive pulmonary disease.

Authors:  Jianchu Zhang; Li Deng; Xianzhi Xiong; Pei Wang; Jianbao Xin; Wanli Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

Review 3.  Toll-like receptor signaling in neural plasticity and disease.

Authors:  Eitan Okun; Kathleen J Griffioen; Mark P Mattson
Journal:  Trends Neurosci       Date:  2011-03-16       Impact factor: 13.837

4.  Modulation of the immune and inflammatory responses by Plasmodium falciparum schizont extracts: role of myeloid dendritic cells in effector and regulatory functions of CD4+ lymphocytes.

Authors:  Ann Maria Clemente; Giulia Fadigati; Roberto Caporale; Damiano G Marchese; Giuseppe Castronovo; Anna Rosa Sannella; Carlo Severini; Federica Verra; Enrico Garaci; Federico Cozzolino; Maria Gabriella Torcia
Journal:  Infect Immun       Date:  2013-03-18       Impact factor: 3.441

5.  Innate immunity in the postmortem brain of depressed and suicide subjects: Role of Toll-like receptors.

Authors:  Ghanshyam N Pandey; Hooriyah S Rizavi; Runa Bhaumik; Xinguo Ren
Journal:  Brain Behav Immun       Date:  2018-09-25       Impact factor: 7.217

6.  TLR2/6 stimulation of the rat lung: effects on lymphocyte subsets, natural killer cells and dendritic cells in different parts of the air-conducting compartments and at different ages.

Authors:  Reinhard Pabst; Deniz Durak; Anna Roos; Anke Lührmann; Thomas Tschernig
Journal:  Immunology       Date:  2008-06-19       Impact factor: 7.397

Review 7.  Toll-like receptors in neurodegeneration.

Authors:  Eitan Okun; Kathleen J Griffioen; Justin D Lathia; Sung-Chun Tang; Mark P Mattson; Thiruma V Arumugam
Journal:  Brain Res Rev       Date:  2008-09-12

8.  TLR2 activation is essential to induce a Th1 shift in human peripheral blood mononuclear cells by plant stanols and plant sterols.

Authors:  Florence Brüll; Ronald P Mensink; Karin van den Hurk; Adriaan Duijvestijn; Jogchum Plat
Journal:  J Biol Chem       Date:  2009-11-30       Impact factor: 5.157

Review 9.  The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis.

Authors:  Sinyi Kong; Pricilla Yeung; Deyu Fang
Journal:  J Genet Genomics       Date:  2013-04-12       Impact factor: 4.275

Review 10.  The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease.

Authors:  Megan E Himmel; Gijs Hardenberg; Ciriaco A Piccirillo; Theodore S Steiner; Megan K Levings
Journal:  Immunology       Date:  2008-10       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.